Abstract
Background. Cardiac disease is a significant cause of morbidity and mortality in children with end-stage renal disease (ESRD). This study aimed to report the frequency of cardiac disease diagnostic methods used in US pediatric maintenance hemodialysis patients. Methods. A cross-sectional analysis of all US pediatric (ages 0.7-18 years, n = 656) maintenance hemodialysis patients was performed using data from the Centers for Medicare and Medicaid Services ESRD Clinical Performance Measures Project. Clinical and laboratory information was collected in 2001. Results were analysed by age, sex, race, Hispanic ethnicity, dialysis duration, body mass index (BMI), primary ESRD cause and laboratory data. Results. Ninety-two percent of the patients had a cardiovascular risk factor (63% hypertension, 38% anemia, 11% BMI >94th percentile, 63% serum phosphorus >5.5 mg/ dL and 55% calcium-phosphorus product ≥55 mg 2 /dL 2 ). A diagnosis of cardiac disease was reported in 24% (n = 155) of all patients: left ventricular hypertrophy/enlargement 17%, congestive heart failure/pulmonary edema 8%, cardiomyopathy 2% and decreased left ventricular function 2%. Thirty-one percent of patients were not tested. Of those tested, the diagnostic methods used were chest X-rays in 60%, echocardiograms in 35% and electrocardiograms in 33%; left ventricular hypertrophy/enlargement was diagnosed using echocardiogram (72%), chest X-ray (20%) and electrocardiogram (15%). Conclusions. Although 92% of patients had cardiovascular risk factors, an echocardiography was performed in only one-third of the patients. Our study raises the question of why echocardiography, considered the gold standard for cardiac disease diagnosis, has been infrequently used in pediatric maintenance dialysis patients, a high-risk patient population.
Introduction
Recognition of cardiac disease as a cause of morbidity and mortality in pediatric patients with end-stage renal disease (ESRD) has increased [1] [2] [3] [4] [5] [6] . However, few data are available regarding the effectiveness of the methods used for cardiac disease diagnosis in pediatric maintenance hemodialysis patients.
The ESRD Clinical Performance Measures (CPM) Project is a national quality assurance programme led by the Centers for Medicare and Medicaid Services (CMS) and the 18 ESRD Networks in an effort to improve patient care for maintenance dialysis patients [7] . In 2002, the ESRD CPM Project collected data on all pediatric (aged 0.7-18 years) in-centre maintenance hemodialysis patients in the USA who were alive on 31 December 2001. Using these data, the goal of the present study was to report the methods used to diagnose cardiac disease and associated characteristics in US pediatric in-centre maintenance hemodialysis patients.
Materials and methods

Data and sources
The methods used to conduct the 2002 ESRD CPM Project have been described [7] . Briefly, in May 2002, a three-page in-centre hemodialysis form and a one-page pediatric in-centre hemodialysis supplemental form were distributed to ESRD facilities. Use of these forms was approved through the National Institutes of Health clinical exemption process. Descriptive information for each patient and hemodialysis facility was printed onto gummed labels and sent to the individual ESRD Networks along with the forms used to collect the data. Experienced staff at 267 dialysis facilities abstracted clinical information in patient medical records for all pediatric in-centre hemodialysis patients (n = 710) who received incentre hemodialysis during three observation periods (October, November and December of 2001). Completed forms were sent to the appropriate ESRD Network for data verification and entry, and were then electronically submitted to the CMS for analysis and reporting. These data were later merged with the United States Renal Data System (USRDS) database, which includes ESRD registration and billing information. Patients with incomplete forms or birth date information that was not in agreement with the USRDS data were excluded (n = 54). The merged datasets yielded data for 656 pediatric patients, who make up the present study population. Some patients who were included may not have had Medicare coverage.
Demographic data included age (0-4, 5-9, 10-14 or 15-18 years), sex, race and Hispanic ethnicity as well as duration of dialysis, primary cause of ESRD, whether care was provided by an adult or pediatric nephrology provider, height, pre-and post-dialysis weight, and pre-and postdialysis blood pressure measures. Pre-dialysis laboratory data included hemoglobin, serum albumin, calcium, phosphorus and intact parathyroid hormone. Urea reduction ratio and single-pool Kt/V values were calculated and used as measures of dialysis adequacy. Patients with the following conditions were classified as having cardiac disease: congestive heart failure (CHF), pulmonary edema (PE), left ventricular hypertrophy (LVH), left ventricular enlargement (LVE), decreased left ventricular (LV) function or cardiomyopathy. Collected cardiac disease data included the testing method used to make the diagnosis and whether any of the tests were performed during the calendar year. Information on the following was not available: indications for cardiac testing, local protocols for assessing cardiac disease, and local definitions used for diagnoses of LVH/LVE, CHF and decreased LV function. Hypertension was defined as systolic or diastolic blood pressure above the 95th percentile for age, height and sex, or use of antihypertensive medication [8] ; hypertension was the subject of a prior report on this patient population [9] . The goal of pharmacologic treatment of hypertension in children is to reduce blood pressure to below the 95th percentile. Therefore, we used the term 'controlled' to indicate blood pressure below the 95th percentile in response to therapy [8] . Blood pressure, post-dialysis weight and laboratory values were averaged for the three study months. Height and body mass index (BMI; kg/m 2 of height) percentiles by age and sex were calculated from tables provided by the Centers for Disease Control and Prevention. Anemia was defined as mean hemoglobin value <11 g/dL [10] .
Data analysis
Statistical analyses, including descriptive statistics, were conducted with the Pearson chi-square test, t-test and logistic regression using the Statistical Analysis System (SAS) software version 9.1 (Cary, NC, USA). Independent variables for predicting cardiac disease prevalence were age, sex, race, Hispanic ethnicity, blood pressure status, primary cause of ESRD (congenital/cystic/hereditary: dysplasia, cystic kidney disease, urologic disease, congenital nephrotic syndrome, oxalosis and Alport syndrome; acquired: glomerulonephritis, interstitial nephritis, vasculitis, chronic pyelonephritis and hypertension; and others), duration of dialysis (0-<6 months, 6-11 months, 1-2.9 years and ≥3 years), BMI percentile (<5%, 5-<85% and ≥85%), and laboratory values. Results are presented as mean ± 1 SD. Two-tailed P-values <0.05 were considered statistically significant.
Results
Patient characteristics are listed in Table 1 . Mean hemodialysis duration was 38 ± 43 months, and the most common duration was ≥3 years (34%). A diagnosis of cardiac disease was reported for 24% (n = 155) of all patients. LVH and/or LVE were the most common cardiac diagnoses (17%), followed by CHF/PE (8%), cardiomyopathy (2%) and decreased LV function (2%; Table 2 ). Cardiac disease diagnosis did not differ significantly between groups defined by age, sex, race, Hispanic ethnicity, primary provider, primary cause of ESRD, dialysis adequacy, serum calcium and phosphorus levels, calcium-phosphorus product, or BMI percentile (Table 1) . Cardiac disease was more frequently diagnosed in patients with than without hypertension (29% vs. 14%, P < 0.0001; Figure 1 ), and in patients with than without anemia (32% vs. 19%, P = 0.0002). A larger percentage of patients with than without cardiac disease had received dialysis for three or more years (45% vs. 31%, P = 0.0009). Rates of cardiac testing varied by provider; 73% of patients under the supervision of a pediatric nephrologist were tested compared with 57% under supervision of an adult nephrologist (P = 0.0001). However, by multivariate logistic regression analysis, higher risk of cardiac disease diagnosis was related only to hypertension [odds ratio (OR) 2.5, P = 0.0002] and anemia (OR 1.6, P = 0.0289; Table 3 ).
Ninety-two percent of patients had a cardiovascular risk factor (63% hypertension, 38% anemia, 11% BMI >94th percentile, 63% serum phosphorus >5.5 mg/dL and 55% calcium-phosphorus product ≥55 mg 2 /dL 2 ). Patients with anemia and hypertension were more likely to undergo cardiac testing than patients without these conditions: anemia versus no anemia (P = 0.04), and hypertension versus no hypertension (P = 0.0005). Overall, 33% of patients who underwent any testing had cardiac disease, and 52% of patients who received echocardiography had cardiac disease (Table 4) . Combining data on general testing and the method used for cardiac diagnosis, chest X-rays were performed for 60% of the cohort, echocardiograms for 35%, and electrocardiograms for 33%. LV Mean (sample size); means are of the total number with non-missing values using the 'green' method of calculating serum albumin. abnormalities were diagnosed by echocardiogram in 72% of patients, by electrocardiogram in 15%, and by combined echocardiogram and electrocardiogram in 6% (Table 2) . CHF/PE was diagnosed by chest X-ray in 80% of patients and by echocardiogram in 22%. Less than 1% of patients underwent planar multigated radionuclide angiography or cardiac catheterization (Table 4) . Of the patients without a cardiac diagnosis, 22% underwent echocardiogram.
Discussion
In this study, we found that a non-invasive method was used for diagnosis of cardiac disease in 98% of patients who underwent a diagnostic test. We found that 31% of maintenance hemodialysis patients underwent no testing for cardiac disease during the year of study, and in those tested, an inferior test (chest X-ray or electrocardiogram) was often used. Echocardiographic evaluation, despite its known ability to identify subclinical cardiac disease even at early stages of chronic kidney disease (CKD), was not used in 65% of patients. Left ventricular hypertrophy and dysfunction are associated with increased risk for cardiovascular disease and mortality in adults on maintenance dialysis [11, 12] . These abnormalities are best assessed by echocardiogram and cannot be accurately detected using only physical examination, chest X-ray or electrocardiogram [13, 14] . Mortality associated with cardiac disease in pediatric maintenance dialysis patients is 1000 times higher than the national pediatric cardiac disease death rate [6] . No study of the frequency of tests used to diagnose cardiac disease in pediatric hemodialysis patients has been previously published. Guidelines for monitoring children on maintenance dialysis did not exist at the time this study was conducted. However, echocardiography has been recommended in the literature since the 1980s for cardiac monitoring in children with CKD [14] [15] [16] [17] .
Previous studies have shown a high prevalence of abnormal LV structure and function in pediatric maintenance dialysis and CKD patients [15] [16] [17] [18] [19] . Hypertrophic cardiomyopathy characterized by asymmetric septal hypertrophy was diagnosed by echocardiography in 4 of 10 (40%) Israeli pediatric maintenance dialysis patients [15] . Right and left ventricular diastolic dysfunction was present in 25 of 25 (100%) pediatric maintenance dialysis patients, but not in 12 kidney transplant patients or 37 age-and sex-matched controls [16] . Severe LVH was diagnosed by echocardiography in 48 of 64 (75%) young pediatric maintenance dialysis patients [17] . In a study from France, LVH was observed by echocardiography at the start of hemodialysis in 14 of 17 (82%) pediatric patients [18] . Using standard echocardiograms in 130 children aged 3-18 years with CKD stages 2-4, a 5-fold increase in systolic dysfunction was found compared with 130 healthy control subjects [19] . Of CKD patients, 25% had lower fractional shortening at the endocardial and midwall levels in the presence of hypertension, increased LV mass and concentric LVH, compared with 5% of control subjects. Systolic dysfunction was associated with anemia in pre-dialysis CKD patients with concentric LVH. Recent Kidney Disease Outcomes Quality Initiative clinical practice guidelines for cardiac disease in dialysis patients recommend performing echocardiography in children once dry weight has been achieved, and screening for traditional cardiovascular risk factors [13] .
We found a high prevalence of cardiovascular risk factors, including anemia, hypertension, obesity and abnormal calcium-phosphorus metabolism [20] [21] [22] . Our results suggest that~30% of pediatric maintenance dialysis patients with hypertension and/or anemia are diagnosed with cardiac disease, and patients with anemia and/or hypertension are more likely to undergo testing for cardiac disease. Hypertension and anemia have been previously reported as risk factors for cardiac disease in pediatric maintenance dialysis patients [13, 15, 17, 18, [20] [21] [22] . These data suggest that the presence of hypertension and/or anemia should be considered an indication for annual testing for cardiac disease in children with ESRD who are receiving maintenance hemodialysis. Surprisingly, despite the high prevalence of cardiac disease risk factors in this study population, only 35% of patients underwent echocardiography. In comparing pediatric versus adult caregivers, we found that pediatricians had a higher rate of ordering diagnostic tests for cardiac disease. The reasons for this difference are not clear, but it may simply be due to familiarity with pediatric patient care. However, this difference was not significant in a multivariate analysis.
Limitations of this study include the lack of information about whether providers required symptoms of cardiac disease to be present before obtaining echocardiograms or other diagnostic tests for cardiac disease; also, the local definitions used for cardiac disease diagnoses were not reported. The data we present were collected in 2002. This is the only year in which the ESRD CPM Project collected the variables needed for this analysis. We acknowledge that practice patterns (including echocardiography) for the diagnosis of cardiac disease in pediatric ESRD may have changed since our data were collected.
In summary, these study results show that (i) a significant number of pediatric maintenance hemodialysis patients have some form of cardiac disease diagnosis; (ii) cardiac disease is more prevalent and more frequently tested for in patients with hypertension or anemia; and (iii) echocardiography is an important tool for diagnosis. Nevertheless, many of the pediatric maintenance hemodialysis patients in our study did not undergo testing for cardiac disease, despite the significant prevalence of cardiac disease risk factors in this population. Protocols for regular screening, diagnosis, and monitoring of cardiac disease and associated risk factors should be incorporated into the care of these patients. Our study raises the question of how frequently echocardiography, considered the gold standard for cardiac disease diagnosis, is used in pediatric maintenance dialysis patients.
